Clinical trial
Effects of Vascular Endothelial Growth Factor Antagonism With Ranibizumab or Bevacizumab in Patients With Neovascular Macular Degeneration
NCT00727753 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Vascular Endothelial Growth Factor Antagonism With Ranibizumab or Bevacizumab in Patients With Neovascular Macular Degeneration
- Lead sponsor
- University of Zurich
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2008
- Completion date
- October 31, 2013
- Enrollment
- 54 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.